Hematology

This is the third regenerative medicine advanced therapy designation granted to AlloVir’s posoleucel therapy.

ADI-001 has been granted a Fast Track Designation by the FDA a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

A look at global access to gene therapy and an overview of the progress in hemophilia treatments.

The chief executive officer of Graphite Bio discusses the phase 1/2 CEDAR trial of GPH101, an investigative Cas9-edited autologous CD34+ cell therapy for the treatment of sickle cell disease.

Review top news and interview highlights from the week ending April 15, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The decision was based on findings from the phase 1 TRANSCEND NHL 001 clinical trial.

The phase 1, investigator-initiated trial continues to recruit participants with B-ALL.

AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.

Review top news and interview highlights from the week ending April 8, 2022.

Iovance plans to complete BLA submission for lifileucel by August 2022.

The phase 3 registration study is evaluating AB-205's efficacy in treating damaged stem cell niches.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The investigational therapy leverages an advanced overnight nonviral gene delivery manufacturing process that may help it overcome existing treatment limitations.

The biotechnology company previously pulled out of Europe after encountering payor challenges for their gene therapies.

The gene therapy ASC618 has received European and US designations and opinions that could help expedite development for hemophilia A.

The FDA has approved second-line axicabtagene ciloleucel as a treatment for adult patients with large B-cell lymphoma following frontline chemoimmunotherapy.

Review top news and interview highlights from the week ending April 1, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Research presented at the EBMT meeting suggests cell expansion may be a good biomarker of both response and outcomes.

Review top news and interview highlights from the week ending March 25, 2022.

A prespecified interim analysis from the phase 3 TRANSFORM study showed an event-free survival benefit with the second-line therapy.

The professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Seven patients from the trial continued to be followed-up as of the data cut-off date.